Deployment o the Multidisciplinary Prospective Cohort Imminent

Summary

Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.

Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment.

These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.

Conditions

• Chronic Inflammatory Disease
• Angioedema
• Severe Asthma
• Lupus
• Atopic Dermatitis
• Psoriatic Arthritis
• Multiple Sclerosis
• Systemic Sclerosis
• Behçet Disease

Interventions

GENETIC

Biobanking with genetic analysis

Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.

OTHER

SF-12 questionnaire

Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.

Sponsors & Collaborators

• FHU IMMINeNT

  collaborator UNKNOWN

• FHU PRECISE: Projet Fédératif Hospitalo-Universitaire PREcision health in Complex Immune-mediated inflammatory diseaSEs

  collaborator UNKNOWN

• Fond de dotation de la Société Française de Dermatologie (SFD)

  collaborator UNKNOWN

• University Hospital, Lille

  lead OTHER

Principal Investigators

• David Launay, MD,PhD · University Hospital, Lille

Study Design

Allocation

NA

Purpose

OTHER

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-20

Primary Completion

2031-07-20

Completion

2031-07-21

Countries

• France

Study Locations